Virtual International Authority File


Postel-Vinay, Sophie Library of Congress/NACO Sudoc [ABES], France National Library of Israel ISNI National Library of France

Sophie Postel-Vinay Wikidata

VIAF ID: 246025754 (Personal)


Open Section Close Section Preferred Forms





Open Section Close Section 4xx's: Alternate Name Forms (2)

Open Section Close SectionWorks

Title Sources
Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development? Wikidata
Cardiac troponin I elevation and overall survival among cancer patients receiving investigational compounds during phase I trials. Wikidata
A Case-Control Study Brings to Light the Causes of Screen Failures in Phase 1 Cancer Clinical Trials Wikidata
Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies. Wikidata
Chromatin Regulators as a Guide for Cancer Treatment Choice. Wikidata
Le ciblage de la voie du VEGF Library of Congress/NACO Sudoc [ABES], France National Library of Israel National Library of France
Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter? Wikidata
Common variants near TARDBP and EGR2 are associated with susceptibility to Ewing sarcoma Wikidata
ERCC1 function in nuclear excision and interstrand crosslink repair pathways is mediated exclusively by the ERCC1-202 isoform. Wikidata
Etude de la déficience en ERCC1 dans le cancer bronchique non-à-petites cellules et recherche de léthalité synthétique. Sudoc [ABES], France
A high-throughput screen identifies PARP1/2 inhibitors as a potential therapy for ERCC1-deficient non-small cell lung cancer. Wikidata
Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1. Wikidata
Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Wikidata
The insulin-like growth factor-I receptor inhibitor figitumumab (CP-751,871) in combination with docetaxel in patients with advanced solid tumours: results of a phase Ib dose-escalation, open-label study. Wikidata
Large-Scale Profiling of Kinase Dependencies in Cancer Cell Lines. Wikidata
Mutational Landscape and Sensitivity to Immune Checkpoint Blockers. Wikidata
Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trials. Wikidata
Patients aged over 75 years enrolled in Phase I clinical trials: the Gustave Roussy experience. Wikidata
The potential of exploiting DNA-repair defects for optimizing lung cancer treatment. Wikidata
Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape. Wikidata
Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score). Wikidata
Rationale for anti-OX40 cancer immunotherapy. Wikidata
Reovirus: Rationale and clinical trial update. Wikidata
Safety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing's sarcoma: a phase 1 expansion cohort study. Wikidata
Synthetic lethality and functional study of DNA repair defects in ERCC1-deficient non-small-cell lung cancer Sudoc [ABES], France
Targeting FGFR Signaling in Cancer. Wikidata

Open Section Close Section Selected Co-authors

Open Section Close Section Countries and Regions of Publication (1)

Open Section Close Section Publication Statistics

Open Section Close Section Selected Publishers (1)

Open Section Close Section About

Open Section Close Section History of VIAF ID:246025754 (6)